Page 1 of 1
(2)EACCME® participant's evaluation form
Vaccination in paediatric transplantation – General recommendations. A position paper by the European Reference Network TransplantChild
Below you will find several questions about the contents and other aspects of the webinar. Once the webinar ends, you have
up to 2 weeks
to submit your answers and get ECMEC®s accreditation certificate.
Please enter your full name as it appears on the registration form:
*
QUESTIONS
1) Patient who is a candidate for solid organ transplantation (SOT) needs to complete the recommended vaccinations before the procedure. According to current recommendations, when should vaccines be administered to ensure an adequate immune response?
*
A
Live vaccines should be administered at least 4 weeks before SOT, and inactivated vaccines at least 2 weeks before SOT.
B
Live vaccines should be administered at least 2 weeks before SOT, and inactivated vaccines at least 1 week before SOT.
C
Live vaccines cannot be administered before SOT, and inactivated vaccines can be administered any time before SOT.
D
Both live and inactivated vaccines can be administered a few days before SOT without affecting the immune response.
2) According to current recommendations, when should inactivated vaccines be initiated in patients who have undergone hematopoietic stem cell transplantation (HSCT)?
*
A
Immediately after transplantation, regardless of immune status or ongoing immunosuppression.
B
Between 3 and 6 months after transplantation, with timing individualized based on immune reconstitution and the absence of significant graft-versus-host disease (GVHD) or ongoing immunosuppression, following expert immunological evaluation.
C
Only after 12 months post-transplantation, regardless of the patient's immune recovery.
D
Between 1 and 2 months after transplantation, provided the patient has no signs of infection or GVHD.
3) Which of the following live attenuated vaccines (LAVs) are contraindicated for household contacts of immunocompromised individuals because of their possible risk of transmission?
*
A
Measles-Mumps-Rubella (MMR) and Varicella vaccines.
B
Live attenuated influenza vaccine (LAIV) and Rotavirus vaccine.
C
Oral Polio Vaccine (OPV) and Smallpox (vaccinia virus) vaccine.
D
Yellow fever vaccine and Bacille Calmette-Guérin (BCG) vaccine.
4) Under which circumstances may live attenuated vaccines (LAVs) be considered for paediatric solid organ transplant (SOT) recipients?
*
A
They can be administered to all paediatric SOT recipients, regardless of immunosuppression level or rejection history.
B
They may be administered only after the first month after transplantation and only in liver and kidney transplanted patients.
C
They may be considered in selected paediatric SOT recipients who have no recent history of rejection and are receiving low levels of immunosuppression, under the guidance of an immunology specialist.
D
They are absolutely contraindicated in all paediatric SOT recipients after transplantation.
5) According to current recommendations, under which conditions may Varicella and Measles-Mumps-Rubella (MMR) vaccines be administered to HSCT recipients?
*
A
At least 12 months after HSCT, regardless of GVHD status or ongoing immunosuppressive therapy.
B
At least 24 months after HSCT in all patients, regardless of serological status.
C
Immediately after HSCT in both in seronegative and seropositive patients, provided they are receiving low-dose immunosuppressive therapy.
D
In seronegative patients, not earlier than 24 months after HSCT, provided they have no graft-versus-host disease (GVHD), have been off immunosuppressive therapy for at least 12 months, and have not received IVIG replacement therapy for 6–9 months.
6) Quality of the event
How useful for your professional activity did you find this event?
*
Not useful
Fairly useful
Useful
Extremely useful
If this activity was not useful, please explain why:
*
What was your overall impression of this event in terms of the
programme
?
*
Very poor
Poor
Good
Excellent
What was your overall impression of this event in terms of the
organisation
?
*
Very poor
Poor
Good
Excellent
What was the
best
aspect of this event?
*
What was the
worst
aspect of this event?
*
7) Relevance of the event
Did the event fulfil your educational goals and expected learning outcomes?
*
Not at all
Not much
Somewhat
Very much
Was the presented information well balanced and consistently supported by a valid scientific evidence base?
*
Not at all
Not much
Somewhat
Very much
How useful to you personally was the session?
*
Not useful
Fairly useful
Useful
Extremely useful
8) Suitability of formats used during the event
Was there adequate time available for discussions, questions & answers and learner engagement?
*
Never
Only rarely
Sometimes
Always/Almost Always
Can you indicate any innovative elements during the activity?
9) Ways the event affects clinical practice
Will the information your learnt be implemented in your practice?
*
Not at all
Not much
Somewhat
Very much
Can you provide ONE example how this event will influence your future practice?
*
10) Commercial bias
Did all the speakers provide their potential conflict of interest declaration with the sponsor(s) as a second slide of their presentations?
*
No
Yes, but only a small part
Yes, for the majority
Yes, all
Can you provide an example of biased presentation in this activity?
*
Do you agree that the information was overall free of commercial and other bias?
*
Strongly disagree
Rather disagree
Rather agree
Strongly agree
Thank you very much for your time!
Submit